Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,074,046
  • Shares Outstanding, K 186,851
  • Annual Sales, $ 4,110 K
  • Annual Income, $ -119,360 K
  • 60-Month Beta 1.01
  • Price/Sales 718.34
  • Price/Cash Flow N/A
  • Price/Book 5.94
Trade INO with:

Options Overview

Details
  • Implied Volatility 137.30%
  • Historical Volatility 158.43%
  • IV Percentile 26%
  • IV Rank 13.91%
  • IV High 453.99% on 03/12/20
  • IV Low 86.12% on 10/09/20
  • Put/Call Vol Ratio 0.40
  • Today's Volume 36,138
  • Volume Avg (30-Day) 70,585
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 216,707
  • Open Int (30-Day) 339,245

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.22
  • Number of Estimates 5
  • High Estimate -0.21
  • Low Estimate -0.26
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.38 +6.94%
on 01/27/21
19.00 -41.58%
on 02/02/21
+0.52 (+4.91%)
since 01/26/21
3-Month
8.62 +28.77%
on 12/29/20
19.00 -41.58%
on 02/02/21
+0.71 (+6.83%)
since 11/25/20
52-Week
3.83 +189.82%
on 03/02/20
33.79 -67.15%
on 06/26/20
+7.11 (+178.20%)
since 02/26/20

Most Recent Stories

More News
INOVIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inovio Pharmaceuticals Inc. - INO

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Inovio Pharmaceuticals...

INO : 11.10 (-3.39%)
Is a Surprise Coming for Inovio (INO) This Earnings Season?

Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

INO : 11.10 (-3.39%)
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

, /PRNewswire/ --   -  The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent headline-grabbing announcements pertaining to COVID-19. A series of discoveries...

ONCY : 3.21 (-7.49%)
ONC.TO : 4.09 (-6.19%)
INO : 11.10 (-3.39%)
REGN : 450.57 (-0.58%)
SNY : 45.89 (+0.20%)
NWBO : 1.4500 (+2.11%)
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent ...

ONCY : 3.21 (-7.49%)
INO : 11.10 (-3.39%)
REGN : 450.57 (-0.58%)
SNY : 45.89 (+0.20%)
NWBO : 1.4500 (+2.11%)
ONC.TO : 4.09 (-6.19%)
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia

and GERMANTOWN, Md. and HILDEN, , /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a...

QGEN : 50.00 (-0.68%)
INO : 11.10 (-3.39%)
QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO's VGX-3100 for Advanced Cervical Dysplasia

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid...

QGEN : 50.00 (-0.68%)
INO : 11.10 (-3.39%)
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced...

INO : 11.10 (-3.39%)
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INO : 11.10 (-3.39%)
Inovio (INO) to Report Q4 Earnings: What's in the Cards?

On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.

LXRX : 7.19 (-3.88%)
INO : 11.10 (-3.39%)
XLRN : 136.16 (+0.21%)
TVTX : 30.82 (+3.77%)
Inovio Pharmaceuticals (INO) Dips More Than Broader Markets: What You Should Know

Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.

INO : 11.10 (-3.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 12.68
2nd Resistance Point 12.26
1st Resistance Point 11.68
Last Price 11.10
1st Support Level 10.68
2nd Support Level 10.27
3rd Support Level 9.69

See More

52-Week High 33.79
Fibonacci 61.8% 22.35
Fibonacci 50% 18.81
Fibonacci 38.2% 15.27
Last Price 11.10
52-Week Low 3.83

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar